Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients
复制标题
DOI：
10.1182/blood-2009-02-204875
复制
发表时间：
2010-02-11
期刊：
影响因子：
20.3
通讯作者：
Chatenoud, Lucienne
中科院分区：
文献类型：
--
作者：
Keymeulen, Bart;Candon, Sophie;Chatenoud, Lucienne
在这里，我们报告了一个独特的情况，在最近发病的1型糖尿病患者中，用人源化cd3特异性单克隆抗体治疗6天，诱导早期和同步的eb病毒（EBV）再激活。病毒学和免疫学分析表明，这种再激活是短暂的、自限性的、孤立的，与ebv特异性t细胞反应的迅速出现有关。抗cd3抗体的使用诱导了短时间的免疫抑制和轻微但明确的t细胞激活迹象，这些迹象先于病毒再激活。肾和胰岛移植后早期监测显示，在给予全剂量免疫抑制治疗后，没有观察到类似的现象。这种EBV再激活在长期内仍然没有明显的临床关注，不应妨碍治疗性抗cd3抗体的进一步开发。这一现象也可能指导新的研究途径，以了解仍不明确的刺激在体内触发EBV再激活的性质。(血。2010;115:1145 - 1155)
Here we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrated that this reactivation was transient, self-limited, and isolated, associated with the rapid advent of an EBV-specific T-cell response. The anti-CD3 antibody administration induced short-lasting immunosuppression and minor yet clear-cut signs of T-cell activation that preceded viral reactivation. Early posttransplant monitoring of renal and islet allograft recipients showed that no comparable phenomenon was observed after the administration of full-dose immunosuppressive therapy. This EBV reactivation remains of no apparent clinical concern over the long term and should not preclude further development of therapeutic anti-CD3 antibodies. This phenomenon may also direct new research avenues to understand the still ill-defined nature of stimuli triggering EBV reactivation in vivo. (Blood. 2010;115:1145-1155)